Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2− metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis

References

• World Health Organization. GLOBOCAN 2012: estimated cancer incidence, mortality and prevelance worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed May 21, 2015.
   Google Scholar
• National Cancer Institute. 2015. SEER Stat Fact Sheets: breast cancer. http://seer.cancer.gov/statfacts/html/breast.html.
   Google Scholar
• Lu J, Steeg PS, Price JE, et al. Breast cancer metastasis: challenges and opportunities. Cancer Res 2009;69:4951-3
   PubMedGoogle Scholar
• Cardoso F, Harbeck N, Fallowfield L, et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J ESMO 2012;23(7 Suppl):vii11-9
   PubMedGoogle Scholar
• National Cancer Institute. SEER Stat Fact Sheets: Breast Cancer 2014. 2014. http://seer.cancer.gov/statfacts/html/breast.html. Accessed September 15, 2014
   Google Scholar
• Montero AJ, Eapen S, Gorin B, et al. The economic burden of metastatic breast cancer: a U.S. managed care perspective. Breast Cancer Res Treat 2012;134:815-22
   PubMed Web of Science ®Google Scholar
• Chitre M, Reimers KM. Considerations for payers in managing hormone receptor-positive advanced breast cancer. Clinicoecon Outcomes Res 2014;6:331-9
   PubMedGoogle Scholar
• Vera-Llonch M, Weycker D, Glass A, et al. Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality. BMC Cancer 2011;11:250
   PubMed Web of Science ®Google Scholar
• Susan G. Komen Foundation. http://ww5.komen.org/. Accessed
   Google Scholar
• Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst 2014;106:
   PubMedGoogle Scholar
• Cadoo KA, Fornier MN, Morris PG. Biological subtypes of breast cancer: current concepts and implications for recurrence patterns. Q J Nucl Med Mol Imag 2013;57:312-21
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Breast Cancer, Version 3.2015. 2015. http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed May 21, 2015
   Google Scholar
• Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-9
   PubMed Web of Science ®Google Scholar
• Xie J, Diener M, De G, et al. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States. J Med Econ 2013;16:278-88
   PubMedGoogle Scholar
• Lewis L, Taylor M, Suriya Ertugyrovna Y, et al. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in Kazakhstan. J Med Econ 2015;18:189-99
   PubMed Web of Science ®Google Scholar
• Xie J, Hao Y, Zhou ZY, et al. Economic evaluations of everolimus versus other hormonal therapies in the treatment of HR/HER2 advanced breast cancer from a US payer perspective. Clin Breast Cancer 2015; 15:e263-76;
   PubMedGoogle Scholar
• Kourlaba G, Rapti V, Alexopoulos A, et al. Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: an economic evaluation study. BMC Health Serv Res 2015;15:307
   PubMed Web of Science ®Google Scholar
• Campone M, Yang H, Faust E, et al. Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western Europe. J Med Econ 2014;17:837-45
   PubMedGoogle Scholar
• Swallow E, Zhang J, Thomason D, et al. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002–2012. Curr Med Res Opin 2014;30:1537-45
   PubMed Web of Science ®Google Scholar
• Whyte JL, Engel-Nitz NM, Teitelbaum A, et al. An evaluation of algorithms for identifying metastatic breast, lung, or colorectal cancer in administrative claims data. Medl Care 2015;53:e49-57
   PubMed Web of Science ®Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9
   PubMed Web of Science ®Google Scholar
• Hurvitz S, Guerin A, Brammer M, et al. Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting. Oncologist 2014;19:901-8
   PubMed Web of Science ®Google Scholar
• Hassett MJ, O'Malley AJ, Pakes JR, et al. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 2006;98:1108-17
   PubMed Web of Science ®Google Scholar
• Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst 2011;103:117-28
   PubMed Web of Science ®Google Scholar
• Li N, Hao Y, Xie J, et al. Everolimus-based therapy versus chemotherapy among patients with HR+/HER2− Metastatic breast cancer: comparative effectiveness from a chart review study. Int J Breast Cancer 2015;2015:1-9
   Google Scholar
• Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012;62:220-41
   PubMed Web of Science ®Google Scholar
• Brem S, Kumar NB. Management of treatment-related symptoms in patients with breast cancer. Clin J Oncol Nurs 2011;15:63-71
   PubMed Web of Science ®Google Scholar
• Burris HA, 3rd, Lebrun F, Rugo HS, et al. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer 2013;119:1908-15
   PubMed Web of Science ®Google Scholar
• Xie J, Hao Y, Zhou ZY, et al. Economic evaluations of everolimus versus other hormonal therapies in the treatment of HR(+)/HER2(−) Advanced breast cancer from a US payer perspective. Clin Breast Cancer 2015;15:e263-76
   PubMedGoogle Scholar